- Home
- ACT vs IMVT Comparison
ACT vs IMVT Comparison
Compare ACT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACT | IMVT |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.0B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACT | IMVT |
|---|---|---|
| Price | $41.86 | $24.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $42.67 | $30.78 |
| AVG Volume (30 Days) | 243.7K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 4.52 | N/A |
| Revenue | ★ $1,235,827,000.00 | N/A |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $33.94 | $13.36 |
| 52 Week High | $44.80 | $29.25 |
Technical Indicators
Market Signals| Indicator | ACT | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 47.09 |
| Support Level | $39.43 | $22.25 |
| Resistance Level | $42.80 | $25.32 |
| Average True Range (ATR) | 0.85 | 1.25 |
| MACD | 0.22 | 0.13 |
| Stochastic Oscillator | 63.36 | 51.69 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.